Researchers from big pharma, academia, and proteomics equipment suppliers at last week’s ACI (Active Communications International) proteomics meeting in Boston, chaired by Steven Naylor, chief technology officer at Beyond Genomics, got a look at a broad sampling of the various approaches to applying proteomics to drug discovery. In fact, the only thing missing was a talk from a HUPO representative touting the advantages of large-scale proteomics projects.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.